ADX 102

Drug Profile

ADX 102

Alternative Names: ADX-102; NS 2; NS-2-Aldeyra

Latest Information Update: 30 Jan 2017

Price : $50

At a glance

  • Originator Aldeyra Therapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants; Malondialdehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Allergic conjunctivitis; Sjogren-Larsson syndrome; Uveitis
  • Preclinical Contact dermatitis; Mucositis
  • Research Inborn error metabolic disorders

Most Recent Events

  • 25 Jan 2017 Aldeyra Therapeutics plans a phase III trial for Sjogren-Larsson Syndrome in USA and Europe
  • 01 Dec 2016 Phase-II clinical trials in Allergic conjunctivitis in USA (Ophthalmic) (NCT03012165)
  • 26 Sep 2016 Aldeyra Therapeutics plans a phase IIa trial for Dry Eye Syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top